Quest Diagnostics (NYSE:DGX) will announce its earnings results before the market opens on Tuesday, April 23rd. Analysts expect the company to announce earnings of $1.36 per share for the quarter. Quest Diagnostics has set its FY 2019 guidance at $6.40 EPS.
Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, February 14th. The medical research company reported $1.36 earnings per share for the quarter, missing the consensus estimate of $1.37 by ($0.01). Quest Diagnostics had a net margin of 9.77% and a return on equity of 15.23%. The firm had revenue of $1.84 billion during the quarter, compared to the consensus estimate of $1.88 billion. During the same period in the prior year, the business posted $1.40 earnings per share. Quest Diagnostics’s quarterly revenue was down 1.4% compared to the same quarter last year. On average, analysts expect Quest Diagnostics to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.
NYSE:DGX opened at $85.75 on Monday. Quest Diagnostics has a 1-year low of $78.95 and a 1-year high of $116.49. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.94 and a quick ratio of 0.87. The firm has a market capitalization of $11.54 billion, a P/E ratio of 13.59, a PEG ratio of 2.02 and a beta of 0.90.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 22nd. Investors of record on Monday, April 8th will be paid a $0.53 dividend. The ex-dividend date is Friday, April 5th. This represents a $2.12 annualized dividend and a dividend yield of 2.47%. Quest Diagnostics’s dividend payout ratio is presently 33.60%.
Several equities analysts recently weighed in on DGX shares. Canaccord Genuity reissued a “buy” rating and issued a $97.00 target price on shares of Quest Diagnostics in a research note on Monday, February 18th. Wolfe Research initiated coverage on shares of Quest Diagnostics in a research report on Tuesday, April 2nd. They set an “underperform” rating for the company. Bank of America cut shares of Quest Diagnostics from a “neutral” rating to an “underperform” rating in a research report on Thursday, January 3rd. Argus cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Thursday, January 31st. Finally, Mizuho set a $106.00 price objective on shares of Quest Diagnostics and gave the stock a “buy” rating in a research report on Friday, February 15th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $102.50.
In other news, Director Gail R. Wilensky sold 8,000 shares of the business’s stock in a transaction dated Friday, February 22nd. The shares were sold at an average price of $87.78, for a total value of $702,240.00. Following the completion of the sale, the director now owns 34,604 shares of the company’s stock, valued at $3,037,539.12. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Michael E. Prevoznik sold 336 shares of the business’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $88.23, for a total transaction of $29,645.28. Following the completion of the sale, the senior vice president now directly owns 42,108 shares of the company’s stock, valued at approximately $3,715,188.84. The disclosure for this sale can be found here. In the last three months, insiders sold 88,106 shares of company stock valued at $7,935,229. 1.86% of the stock is currently owned by company insiders.
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Further Reading: How to Use the New Google Finance Tool
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.